[New European approval: Idecabtagene vicleucel in relapsed and/or refractory myeloma after at least 3 lines of treatment]

Bull Cancer. 2022 Feb;109(2):113-114. doi: 10.1016/j.bulcan.2021.10.007. Epub 2022 Jan 19.

[Article in French]

Authors

Carolyne Croizier¹, Zoé Van de Wyngaert²

Affiliations

¹ CHU d'Estaing, service de thérapie cellulaire et d'hématologie clinique adulte, 63000 Clermont-Ferrand, France. Electronic address: ccroizier@chu-clermontferrand.fr.
² AP-HP, hôpital Saint-Antoine, Sorbonne université, hématologie clinique et thérapie cellulaire, Inserm UMRs 938, 75012 Paris, France.

PMID: 35063182
DOI: 10.1016/j.bulcan.2021.10.007

No abstract available

Keywords: CAR-T BCMA; CAR-T BCMA.; Idecabtagene vicleucel; Immunotherapy; Immunothérapie; Myeloma; Myélome multiple.

Publication types

Letter

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use*
Drug Approval
Europe
Humans
Multiple Myeloma / drug therapy*
Receptors, Chimeric Antigen / therapeutic use*
Recurrence

Substances

Antineoplastic Agents, Immunological
Receptors, Chimeric Antigen
idecabtagene vicleucel